MarketInOut Stock Screener Log In | Sign Up
 

Aurinia Pharmaceuticals Inc

NASDAQ • Healthcare • Biotechnology • Quote as of 10/16/2026
Aurinia Pharmaceuticals Inc stock price and volume chart

Company Profile

IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization2,209.98 mln
Float118 mln
Earnings Date10/29/2026

EPS

2.32
Solid

P / E

7.12
Undervalued

Piotroski F-Score

8 / 9
Very strong

Beneish M-Score

9.44
Highly suspicious

Relative Strength

90 / 100
Top performer

Debt / Equity

0.10
Very low leverage

Business Description

Aurinia Pharmaceuticals is a Canadian company focused on treating patients with serious autoimmune conditions that currently have few effective options. Its main product, LUPKYNIS, is a pill taken by mouth to help adults manage lupus nephritis, a severe kidney disease caused by lupus. The company is also working on an experimental drug called aritinercept, which targets two proteins believed to drive autoimmune disease. Founded in 1993 and based in Edmonton, Aurinia sells its treatments primarily in the United States and Japan.

Key Fundamentals

EPS2.32
P/E7.12
ROE63.72
RPS2.37
ROIC59.27
ROA47.35
Interest Cover34.25
EBITDA, mln184
EV / EBITDA9.72
EV / EBIT10.86
Revenue, mln312
EV / Revenue5.73

Quote Details

Last 16.51
Change -0.22 (-1.31%)
Open 16.81
Volume 736,075
Turnover 12,152,598
Average Volume 844,945

Financial Ratios

Pre-Tax Profit Margin51
Leverage Ratio1.29
Current Ratio5.42
Price / Book3.50
Price / Tangible Book3.52
Price / Cash Flow12.44
Price / Free Cash Flow12.67
Debt / Equity0.10
Price / Sales7.07

Financial Strength

Altman Z-Score8.12
Piotroski F-Score 8 / 9
Beneish M-Score9.44
Price to Intrinsic Value5.38
Price to Graham Number1.05
Short Ratio9.71
Short % of Float6.57

Price Performance & Relative Strength

Period Price Performance Relative Strength
1 Week -0.84% 56 / 100   
1 Month -2.65% 47 / 100   
2 Months 2.99% 80 / 100   
6 Months 2.87% 66 / 100   
1 Year 43.94% 91 / 100   



Disclaimer - Privacy Policy - Terms Of Service - Cookie Use Policy - FAQ - Contact Us